RGN-259 eye drops for neurotrophic keratopathy with persistent corneal defects
Part of Eyes & vision clinical trials.
This Phase 3 trial tests whether a 0.1% RGN-259 eye drop can safely improve a stubborn corneal wound in adults with neurotrophic keratopathy (nerve-related corneal healing problems). You may qualify if you still have an eye surface defect after at least a week of standard treatments, and you meet specific measurements for corneal sensitivity and vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign consent and follow study visit instructions
- Have a persistent corneal epithelial defect (corneal surface wound) in at least one eye that did not heal after 1 week of standard treatments (like non-preserved lubricants, antibiotics, doxycycline, patching, amniotic membrane, serum tears, and/or therapeutic contact lenses)
- Have stage 2 or 3 neurotrophic keratopathy in at least one eye, and the defect is at least 1 mm long, and your doctor confirms it’s not just minor, superficial irritation
- Have reduced corneal feeling (corneal sensitivity) of 40 mm or less on a specific test, and your vision in the study eye meets a certain threshold (ETDRS 75 letters or worse or equal)
- If you can become pregnant: use an agreed form of birth control and be non-lactating, with a negative pregnancy test; if male: agree to use contraception
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether your own platelet-rich plasma can help heal a fragile, slow-to-recover cornea caused by reduced corneal feeling (nerve damage). It may help reduce corneal erosion and improve corneal surface healing.
This trial tests whether KB801 can help heal persistent corneal defects better than a placebo. It is for people with neurotrophic keratitis (a condition where the cornea loses sensation) that has not improved with standard care.
This trial tests whether a new eye drop called Lacripep can help treat neurotrophic keratitis, a rare eye condition where the cornea loses sensation and can become damaged. The study compares Lacripep to a placebo (inactive) drop to see if it improves corneal healing and vision.
This trial tests an experimental eye drop (STSP-0902) for a condition called neurotrophic keratitis, where the cornea (the clear front part of the eye) gets scratches or sores because nerves are damaged. The drop contains a growth factor to help the eye heal. You might be eligible if you have a persistent scratch or sore on your cornea that has not improved for at least a week.
This Phase 2 trial tests BRM424 eye drops in adults with neurotrophic keratitis (a weakened, slow-healing cornea) to see if they help and are safe over 28 days. You may be able to join if your condition matches Stage 2 or Stage 3 and you meet the safety rules.
This trial tests a new eye drop (acoltrepon) to see if it helps people with stage 1 neurotrophic keratopathy (a condition where the cornea's nerves are damaged, causing dry eyes and vision problems) and low tear production. It aims to improve signs like corneal staining and symptoms of discomfort.
Hear when a new Neurotrophic Keratopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.